Margitta Worm

Jul 30, 2024 | ascpt.onlinelibrary.wiley.com | Emma Guttman-Yassky |Michael J. Cork |Margitta Worm |Matthew P. Kosloski

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Interleukin-33 (IL-33), a proinflammatory alarmin cytokine released by damaged epithelial tissue cells, initiates and amplifies both type 1 and type 2 inflammatory cascades. IL-33 has been suggested as having a role in atopic dermatitis (AD), a chronic, relapsing type 2 inflammatory disease of the skin. Itepekimab is a novel human IgG4P monoclonal antibody against IL-33, currently in development for chronic obstructive pulmonary disease (COPD).

Jan 17, 2024 | healio.com | Richard Gawel |Kristen Dowd |John Oppenheimer |Margitta Worm

John J. Oppenheimer, MD As pointed out by the authors, epidemiologic data regarding occupational anaphylaxis are woefully scant. The difficulty in doing such research becomes evident when one considers that the authors began with 5,851 cases with occupational information, but ultimately only 225 (3.8%) anaphylactic episodes were considered to be caused by an occupational allergen. In light of these small numbers, it is difficult to read too much into these findings.